在70%使用基因编辑技术的早期试验病人中,生物Nxt的癌症药物BNX-21减缩了肿瘤。 BioNxt's cancer drug BNX-21 shrank tumors in 70% of early trial patients using gene-editing tech.

2025年12月9日,生物技术公司BioNxt Development于2025年12月9日宣布,其实验性癌症治疗BNX-21在早期临床试验中取得了有希望的成果,70%的参与者观察到肿瘤显著减少。 BioNxt Advances, a biotechnology company, announced on December 9, 2025, that its experimental cancer treatment, BNX-21, has shown promising results in early clinical trials, with significant tumor reduction observed in 70% of participants. 该公司计划向林业发展局提交数据,以便加速核准,并在2026年年中之前启动第三阶段的试验。 The company plans to submit data to the FDA for accelerated approval and initiate Phase 3 trials by mid-2026. 该疗法采用新的基因编辑方法,针对癌症细胞,同时保留健康组织。 The therapy uses a novel gene-editing approach to target cancer cells while sparing healthy tissue.